What should be the endpoints of a symptomatic drug and its control?

Lancet Haematol. 2017 May;4(5):e197-e198. doi: 10.1016/S2352-3026(17)30055-8.
No abstract available

MeSH terms

  • Bridged-Ring Compounds / pharmacology
  • Bridged-Ring Compounds / therapeutic use
  • Endpoint Determination*
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Nitriles
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Randomized Controlled Trials as Topic*

Substances

  • 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
  • Bridged-Ring Compounds
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinase 2